Literature DB >> 27623759

Validation of current procedural terminology codes for rotavirus vaccination among infants in two commercially insured US populations.

Veena Hoffman1, Nicholas J Everage2, Scott C Quinlan3, Kathleen Skerry2, Daina Esposito3, Nicolas Praet4, Dominique Rosillon4, Crystal N Holick3, David D Dore2,5.   

Abstract

PURPOSE: We validated procedure codes used in health insurance claims for reimbursement of rotavirus vaccination by comparing claims for monovalent live-attenuated human rotavirus vaccine (RV1) and live, oral pentavalent rotavirus vaccine (RV5) to medical records.
METHODS: Using administrative data from two commercially insured United States populations, we randomly sampled vaccination claims for RV1 and RV5 from a cohort of infants aged less than 1 year from an ongoing post-licensure safety study of rotavirus vaccines. The codes for RV1 and RV5 found in claims were confirmed through medical record review. The positive predictive value (PPV) of the Current Procedural Terminology codes for RV1 and RV5 was calculated as the number of medical record-confirmed vaccinations divided by the number of medical records obtained.
RESULTS: Medical record review confirmed 92 of 104 RV1 vaccination claims (PPV: 88.5%; 95% CI: 80.7-93.9%) and 98 of 113 RV5 vaccination claims (PPV: 86.7%; 95% CI: 79.1-92.4%). Among the 217 medical records abstracted, only three (1.4%) of vaccinations were misclassified in claims-all were RV5 misclassified as RV1. The medical records corresponding to 9 RV1 and 15 RV5 claims contained insufficient information to classify the type of rotavirus vaccine.
CONCLUSIONS: Misclassification of rotavirus vaccines is infrequent within claims. The PPVs reported here are conservative estimates as those with insufficient information in the medical records were assumed to be incorrectly coded in the claims.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  health insurance claims data; pharmacoepidemiology; positive predictive value; rotavirus vaccination; validation

Mesh:

Substances:

Year:  2016        PMID: 27623759     DOI: 10.1002/pds.4085

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  5 in total

1.  Rotavirus vaccination and short-term risk of adverse events in US infants.

Authors:  J Bradley Layton; Anne M Butler; Catherine A Panozzo; M Alan Brookhart
Journal:  Paediatr Perinat Epidemiol       Date:  2018-07-26       Impact factor: 3.980

2.  Vaccines for preventing rotavirus diarrhoea: vaccines in use.

Authors:  Karla Soares-Weiser; Hanna Bergman; Nicholas Henschke; Femi Pitan; Nigel Cunliffe
Journal:  Cochrane Database Syst Rev       Date:  2019-10-28

3.  Estimating the Effectiveness of Rotavirus Vaccine Schedules.

Authors:  Anne M Butler; Alexander Breskin; John M Sahrmann; M Alan Brookhart
Journal:  Epidemiology       Date:  2021-07-01       Impact factor: 4.860

4.  Vaccines for preventing rotavirus diarrhoea: vaccines in use.

Authors:  Karla Soares-Weiser; Hanna Bergman; Nicholas Henschke; Femi Pitan; Nigel Cunliffe
Journal:  Cochrane Database Syst Rev       Date:  2019-03-25

5.  Safety study of live, oral human rotavirus vaccine: A cohort study in United States health insurance plans.

Authors:  Veena Hoffman; Remon Abu-Elyazeed; Cheryl Enger; Daina B Esposito; Michael C Doherty; Scott C Quinlan; Kathleen Skerry; Crystal N Holick; Peter Basile; Leonard R Friedland; Nicolas Praet; Stéphanie Wéry; Corinne Willame; David D Dore; Dominique Rosillon
Journal:  Hum Vaccin Immunother       Date:  2018-04-13       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.